Seroatlas · Human Serome Atlas

CBR4

3-oxoacyl-[acyl-carrier-protein] reductase

Also known as: CBR4_HUMAN, FLJ14431, SDR45C1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8N4T8
Gene: CBR4
Ensembl: ENSG00000145439
Chromosome: 4
Canonical length: 237 aa
Protein class: Enzymes, Metabolic proteins, Predicted intracellular proteins
Quaternary structure: Homotetramer

OverviewNCBI Gene

Enables several functions, including 3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activity; NADPH binding activity; and NADPH dehydrogenase (quinone) activity. Involved in fatty acid biosynthetic process; glycoside metabolic process; and protein tetramerization. Located in mitochondrial matrix. Part of oxidoreductase complex. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

237 residues, UniProt reviewed canonical sequence.

>Q8N4T8|CBR4
     1  MDKVCAVFGG SRGIGRAVAQ LMARKGYRLA VIARNLEGAK AAAGDLGGDH LAFSCDVAKE
    61  HDVQNTFEEL EKHLGRVNFL VNAAGINRDG LLVRTKTEDM VSQLHTNLLG SMLTCKAAMR
   121  TMIQQQGGSI VNVGSIVGLK GNSGQSVYSA SKGGLVGFSR ALAKEVARKK IRVNVVAPGF
   181  VHTDMTKDLK EEHLKKNIPL GRFGETIEVA HAVVFLLESP YITGHVLVVD GGLQLIL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CBR4 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.25
Highest tissue expression: 46 nTPM

Expression across tissuesHPA

Tissue

liver: 46 nTPM
kidney: 26 nTPM
epididymis: 19 nTPM
heart muscle: 17 nTPM
retina: 16 nTPM
skeletal muscle: 16 nTPM

Single-cell type

cardiomyocytes: 5,958 nCPM
distal convoluted tubule cells: 340 nCPM
medullary thymic epithelial cells: 326 nCPM
myonuclei: 304 nCPM
fibro-adipogenic progenitors: 280 nCPM
podocytes: 271 nCPM

Immune cell

basophil: 7.9 nTPM
naive B-cell: 7.6 nTPM
gdT-cell: 6.7 nTPM
eosinophil: 6.4 nTPM
memory CD8 T-cell: 6.4 nTPM
naive CD8 T-cell: 6.4 nTPM

Brain region

white matter: 36 nTPM
pons: 32 nTPM
cerebellum: 31 nTPM
basal ganglia: 31 nTPM
hypothalamus: 31 nTPM
thalamus: 31 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.7
gnomAD pLI: 0
gnomAD missense Z: 0.08
DepMap mean gene effect: -0.01
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CBR4 as an antibody target. Whether an autoantibody or antibody against CBR4 could matter depends on whether native CBR4 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CBR4 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label CBR4 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...